A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study Of Lurasidone For The Maintenance Treatment Of Subjects With Schizophrenia
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00008670/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
Lurasidone HCI is a compound that is FDA-approved for the treatment of schizophrenia. This
clinical study is designed to test the hypothesis that Lurasidone is effective in the long
term maintenance treatment of schizophrenia.
提供机构：
Vivli
创建时间：
2022-12-15
